Patent · US Active

Biomarkers of response to NAE inhibitors

US10953013B2 · kind B2 · utility

0Cited by

4References

12Claims

0Family size

Assignees

Millennium Pharmaceuticals, Inc. · US
The General Hospital Corporation · US

Inventors

Cyril Benes · Boston, US
Stephen J. Blakemore · Littleton, US
Jonathan L. Blank · Westborough, US
Eric S. Lightcap · Natick, US
George J. Mulligan · Lexington, US
Matthew C. Schu · Somerville, US
Peter Smith · Arlington, US
Jeffrey E. Settleman · Newton, US

Key dates

Filing date	Jun 3, 2016
Grant date	Mar 23, 2021
Priority date	—
Expiry date	Jun 3, 2036

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A90/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.